• News Archive
  • Simaster
  • Webmail
  • Directory
  • Crisis Center
  •  English
    • Indonesia
Universitas Gadjah Mada Universitas Gadjah Mada Universitas Gadjah Mada Universitas Gadjah Mada
  • Education
    • Doctoral dissertation
    • Inauguration of Professor
    • Graduation
  • Achievement
  • Research and Innovation
    • Research
    • Innovation
  • Campus Info
    • Cooperation
    • Seminar and Workshop
    • Student Community Service Program
    • Other
  • News Report
  • Home
  • News Report
  • UGM Expert: Having An Efficacy Rate of 65.3 Percent, Sinovac Vaccine Remains Safe

UGM Expert: Having An Efficacy Rate of 65.3 Percent, Sinovac Vaccine Remains Safe

  • 12 January 2021, 16:33 WIB
  • By: Salma
  • 14001
Miliki 65,3 Persen Efikasi, Vaksin Sinovac Aman

The long-awaited moment has arrived. The announcement of the Sinovac vaccine clinical trial results and the issuance of an Emergency Use Authorization (EUA) to PT Bio Farma as the vaccine carrier in Indonesia are finally all set. The announcement has answered at least most questions regarding its efficacy and safety.

The Sinovac vaccine, which showed an efficacy of 65.3 percent, is declared safe. It has side effects but mild and reversible. Concerns related to antibody-dependent enhancement (ADE), as many mentioned on social media and feared, did not occur in the Sinovac clinical trial in Indonesia, Turkey, and Brazil.

“But perhaps, this raises queries too. Why is the efficacy lower than in Turkey or Brazil? How come it’s lower than the Pfizer and Moderna vaccines, which are said to be up to 90 percent?” said Prof. Dr. apt. Zullies Ikawati, Head of the Doctoral Program in Pharmacy Science, responded to BPOM’s (Indonesian food and drug monitoring agency) announcement of the vaccine test results at the Faculty of Pharmacy UGM on Tuesday (12/1).

Zullies explained a vaccine with 65.3 percent efficacy in clinical trials meant a 65.3 percent reduction in disease cases in the vaccinated group against the unvaccinated (or placebo) group. And that occurred in a controlled clinical trial. For example, she described the Sinovac clinical trial in Bandung involving 1,600 people; 800 subjects who received the vaccine and 800 subjects who received a placebo (blank vaccine).

If 26 of the vaccinated group infected (3.25 percent), while 75 of the placebo group contracted Covid-19 (9.4 percent), then the efficacy of the vaccine was = (0.094 – 0.0325)/0.094 x 100 percent = 65.3 percent. So, what determines the results is the ratio between the vaccinated group and the unvaccinated one.

“The test subject characteristics will also influence efficacy. If the test subject is a high-risk group, the placebo group will likely be exposed more. Hence the calculation of its efficacy will increase,” she explained.

For example, Zullies said there were 26 infected in the vaccinated group, while there was a rising infection to 120 in the placebo group, the efficacy will increase to 78.3 percent. Clinical trials in Brazil used a high-risk group, namely health workers, thus leading to a higher efficacy rate. Meanwhile, Indonesia used the general population with a smaller risk.

“If the test subjects are at low risk and stay at home a lot, let alone adhere to the health protocols, it is highly possible that not many will be infected in the placebo group. It results in a lower ratio of incidence of infection between the placebo group and the vaccinated group, which leads to a lower vaccine efficacy rate. There may also be other factors that influence the clinical trial results,” she explained.

The question is whether the efficacy of that size has a significant impact. According to Zullies, a reduction in the incidence of infection in the population by about 65 percent will certainly be significant and have a long aftereffect. Out of 100 million Indonesians without vaccination means 8.6 million can be infected. If it then drops by 65 percent with vaccination, only 3 million people are infected.

The calculation is (0.086 – 0.03)/0.086 x 100 percent = 65 percent, meaning it can prevent 5.6 million incidents of infection. Preventing 5 million incidents of infection is, by all means, very meaningful in the provision of health care facilities. Not to mention that it can indirectly prevent further transmission for people who do not get the vaccine. Namely that if they can achieve herd immunity.

“As a researcher, I still have hopes for vaccination. Hopefully, it can reduce the incidence of Covid-19 infection in Indonesia. Moreover, if supported by compliance with proper health protocols, hopefully, it can end the Covid-19 pandemic in Indonesia,” she said.

The result of the efficacy of the Sinovac vaccine of 65.3 percent for some people may be disappointing. Yet, it is a big move to start, especially since the minimum limit of the FDA, WHO, and EMA for approval of a vaccine is 50 percent. It means that, epidemiologically, reducing the incidence of infection by 50 percent is highly meaningful and saves the lives of many people.

“Moreover, as announced, the vaccine has high immunogenicity, reaching 99 percent in the first three months. Meaning it can trigger antibodies in subjects who received the vaccine. Of course, we still have to wait for the vaccine effectiveness after the people use it. And keep in mind that since this is only the EUA coming from the interim report, observations on the efficacy and safety will still be carried out for the next six months to get full approval,” she explained.

Author: Agung Nugroho
Photo: Detik-Health

Related News

  • Vaccinated People Have a Low Covid-19 Risk

    Friday,15 January 2021 - 10:46
  • Virology Expert: Vaccine is Not One and Only Solution to Stop Covid-19

    Tuesday,18 August 2020 - 10:41
  • UGM Expert Pleads People to Stop Doubting the "Halal" Certification of the Sinovac Vaccine

    Tuesday,12 January 2021 - 17:57
  • Understanding the Importance of Covid-19 Vaccines

    Friday,22 January 2021 - 16:41
  • New Covid Variant of B.1.1.7 Won't Escape from Vaccine Efficacy

    Friday,05 March 2021 - 11:16

News Releases

  • Geography Alumna’s Aromatic Telon Oil Habbie Named 2023 Indonesia Brand Champion 03 February 2023
    Novita Anggraeni, an alumna of the UGM Faculty of Ge
    Salma
  • Bimasakti UGM Kicks Off Hybrid Technology Research 03 February 2023
    Bimasakti UGM has started researching hybrid technol
    Salma
  • 18,964 UGM Students Receive Scholarships, Director of Student Affairs Says 20 January 2023
    Universitas Gadjah Mada (UGM) annually allocates hundreds
    Salma
  • Prof. Budi Setiadi Daryono Recounts Origin of His Apple Melon Cultivar 'Hikapel' 16 January 2023
    In 2012, a team of researchers from the UGM Facult
    Salma
  • UGM Graduate Fajar Kelana Named Top 20 International James Dyson Award Winner 13 January 2023
    Fajar Sidik Abdullah Kelana, an alumnus of UGM and
    Salma

Event

No latest event at this time

Universitas Gadjah Mada
UNIVERSITAS GADJAH MADA
Bulaksumur Yogyakarta 55281
   info@ugm.ac.id
   +62 (274) 588688
   +62 (274) 565223
   +62 811 2869 988

PARTNERSHIP

  • Alumni
  • International Affairs

ABOUT UGM

  • Rector's Welcome
  • History
  • Vission and Mission
  • The Board of Executive
  • Management

VISIT UGM

  • Campus Map
  • Event

REGISTRATION

  • Undergraduate
  • Graduate
  • Vocational School
  • Professional Program
  • International Program

© 2023 Universitas Gadjah Mada

PRIVACY POLICYCONTACT